Immunotherapy Breakthrough Hodgkin Lymphoma Patients (VIDEO) Dana-Farber Cancer Institute This video is under embargo. Please login to access this video. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Caption Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission, reported in a study published in the New England Journal of Medicine and presented at the annual meeting of the American Society of Hematology. Credit Dana-Farber Cancer Institue Usage Restrictions EMBARGOED until Saturday, Dec. 6, 2014, 1 p.m. ET License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.